Angie Puño

happiness is a butterfly 🦋 Lana Del Rey coded. poetry and medicine 🩵

[Angie Puño @Angiepu2]

Tú y yo siempre seremos eternas. ❤️🙏 Gracias por llegar a mi vida y por formar parte de cada etapa. Te amo infinitamente ❤️

[Angie Puño @Angiepu2]

Si he construido una identidad alrededor del sufrimiento, ¿recuperarme implica perder una parte de mí?

[Rohit Malde @roxboxfix]

1st Line EGFR + mNSCLC Rx options
Thinking beyond Flaura

Resistance Mechanisms

2nd Line Rx Options

Sequencing Evolving
More options evolving

[Dr Rupam Manna MD @DrRupamOncology]

Stage II/III Melanoma Management — The 2026 Update 🧵

The management paradigm has shifted beyond surgery alone.

✅ Wide local excision with appropriate margins
✅ SLNB for T1b and above
✅ No routine completion lymph node dissection (MSLT-II)
✅ Adjuvant anti–PD-1 therapy for high-risk resected disease
✅ Dabrafenib + Trametinib for BRAF V600-mutant Stage III
✅ Neoadjuvant immunotherapy (NADINA, SWOG S1801) is redefining the standard for resectable macroscopic Stage III melanoma with response-adapted treatment.

A concise infographic summarizing current evidence, landmark trials, and exam pearls for oncology trainees.

#Melanoma #SkinCancer #MedicalOncology #Oncology #Immunotherapy #Neoadjuvant #Pembrolizumab #Nivolumab #Ipilimumab #BRAF #TargetedTherapy #Surgery #ESMO #ASCO #DrNB #DMMedicalOncology #MedEd #FOAMed #CancerEducation #OncologyTwitter #CancerConceptsExplained

[Dr Rupam Manna MD @DrRupamOncology]

🧬 Advanced Melanoma (Stage IV/Unresectable): High-Yield Management Algorithm

Immunotherapy is the preferred first-line treatment for all patients, irrespective of BRAF mutation status. Remember the key sequencing pearl from DREAMseq: Immunotherapy first → Targeted therapy later (unless rapid disease control is required).

Also covers:
✅ CheckMate-067
✅ RELATIVITY-047
✅ DREAMseq
✅ COMBI-d/COMBI-v
✅ CheckMate-204
✅ Lifileucel (TIL therapy)
✅ Brain metastases management
✅ Common exam mistakes & revision pearls

Perfect for DrNB Medical Oncology, DM, ESMO & board exam revision.

#Melanoma #SkinCancer #MedicalOncology #Oncology #Immunotherapy #TargetedTherapy #BRAF #Nivolumab #Ipilimumab #Relatlimab #Lifileucel #CancerEducation #FOAMed #MedEd #DrNB #DMOncology #ESMO #ASCO #OncoTwitter #CancerConceptsExplained

[≽^• ˕ • ྀི≼ @areeeyaaarrr]

me when i finally stand up for myself but end up crying instead 🥹

[Angie Puño @Angiepu2]

🌹🌹🌹🌷🌷🌷🌻🌻🌹🌹🌹🌹

[Dilo con dibujos @dilocondibujos_]

Yo aguantándome las ganas de contestar mal:

[Rohit Malde @roxboxfix]

Capecitabine + Oxaliplatin
Chemo Regimen

COLORECTAL cancers

Doses
Indications
Toxicity and Grading
Dose Reductions and Stopping Rules

A simple Glance for Oncologists in Clinics

[Erman Akkus @Erman_Akkus]

🏥TNT strategies in rectal cancer

#cancer #oncology #MedX @OncoAlert

[MV Chandrakanth @ChandrakanthMv]

The MONARCH Trials — The Complete Abemaciclib Story

From metastatic HR+/HER2− breast cancer to high-risk early breast cancer, HER2-positive disease, and CDK4/6 inhibitor continuation beyond progression, the MONARCH program has defined the clinical role of abemaciclib across the breast cancer continuum.

This infographic provides a one-glance visual summary of the key MONARCH trials and their major clinical take-home messages.

What trial from the MONARCH program has had the greatest impact on your clinical practice?

#BreastCancer #bcsm #Oncology #MedTwitter #Abemaciclib #CDK46 #MONARCH #MedicalEducation #MVOnco

[Félicité & Sebastián @verspoem]

A veces pienso que una de las mayores muestras de cariño es la curiosidad. Preguntar, escuchar, recordar detalles. Hay personas que dicen quererte y nunca han sentido interés por descubrir quién eres realmente.

[MV Chandrakanth @ChandrakanthMv]

How long do our landmark melanoma therapies keep patients alive?

A simple memory aid for the approximate median overall survival reported in pivotal trials:

1.5 → 2 → 3 → 4.5 → 6 years

• Ipilimumab
• Dabrafenib + Trametinib*
• Nivolumab
• Nivolumab + Relatlimab†
• Nivolumab + Ipilimumab

This is not a head-to-head comparison—each value comes from different pivotal trials with different patient populations and follow-up. It's simply a practical way to remember the magnitude of benefit achieved across the evolution of metastatic melanoma therapy.

*BRAF V600-mutant melanoma only.
†Approximate landmark OS from 5-year follow-up; mature median OS has not yet been formally reported.

Which number do you remember first: 1.5, 2, 3, 4.5, or 6?

#Melanoma #Oncology #MedTwitter #FOAMed #Immunotherapy #BRAF #MedicalOncology #MVOnco

[Mauricio Ambriz @AmbrizMau]

Evaluación y tratamiento de la deficiencia de hierro:

JAMA 2025;333(20):1813-1823.

[Angie Puño @Angiepu2]

I’m a graveyard of his intentions

[Angie Puño @Angiepu2]

Pretty sad for a girl so in love 🥀

[Luis Moreno Sánchez @radioncoluis]

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I

https://t.co/M2JsBqwAU7

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update

https://t.co/JNfephHD5E